Table 3.
Univariate and multivariate analyses of factors associated with survival and recurrence
| OS | RFS | |||||
|---|---|---|---|---|---|---|
| P* | Multivariate | P* | Multivariate | |||
| HR(95 %) | P | HR(95 %) | P | |||
| Age, y | 0.855 | NA | NA | 0.976 | NA | NA |
| Gender, male/female | 0.852 | NA | NA | 0.572 | NA | NA |
| a-Fetoprotein >400 vs. ≤ 200 ng/dL | 0.209 | NA | NA | 0.064 | NA | NA |
| Tumor size, >5 vs. ≤ 5 cm | 0.005 | 1.699(1.203-2.685) | 0.038 | 0.016 | 1.478(0.856-2.554) | 0.161 |
| Encapsulation complete vs. none | 0.735 | NA | NA | 0.942 | NA | NA |
| Tumor differentiation, III–IV vs. I–II | 0.026 | 1.217(0.715-2.072) | 0.468 | 0.015 | 1.157(1.103-2.584) | 0.026 |
| BCLC stage, C vs. B vs. A | 0.003 | 1.783(1.265-2.564) | 0.027 | 0.003 | 1.768(0.949-3.295) | 0.073 |
| Recurrence, yes vs. no | 0.062 | NA | NA | 0.052 | NA | NA |
| Peritumoral HMGB1, high vs. low | 0.001 | 1.872(1.148-3.053) | 0.009 | 0.002 | 1.697(1.035-2.783) | 0.014 |
| Intratumoral HMGB1, high vs. low | 0.028 | 1.270(0.745-2.166) | 0.462 | 0.060 | NA | NA |
| Peritumoral CD68, high vs. low | 0.017 | 1.567(1.058-2.563) | 0.039 | 0.026 | 1.532(1.127-2.531) | 0.037 |
| Intratumoral CD68, high vs. low | 0.952 | NA | NA | 0.823 | NA | NA |
Abbreviations: y year, BCLC Barcelona clinic liver cancer, NA not adopted
*Univariate analysis